These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 186373)

  • 21. Immunosuppression: a means to assess the role of the immune response in acute virus infections.
    Nathanson N; Cole GA
    Fed Proc; 1971; 30(6):1822-30. PubMed ID: 5001450
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor.
    Fietze E; Prösch S; Reinke P; Stein J; Döcke WD; Staffa G; Löning S; Devaux S; Emmrich F; von Baehr R
    Transplantation; 1994 Sep; 58(6):675-80. PubMed ID: 7940686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects.
    Just-Nübling G; Korn S; Ludwig B; Stephan C; Doerr HW; Preiser W
    Infection; 2003 Oct; 31(5):318-23. PubMed ID: 14556056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus infection in Penang: a serological survey.
    Madhavan HN; Ong KH; Anuar K
    Southeast Asian J Trop Med Public Health; 1986 Jun; 17(2):168-71. PubMed ID: 3024324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human cytomegalovirus: a review of developments between 1970 and 1976. Part II. Experimental developments.
    Michelson-Fiske S
    Biomedicine; 1977 Apr; 26(2):86-97. PubMed ID: 194635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match.
    Webb JR; Lee SH; Vidal SM
    Genes Immun; 2002 Aug; 3(5):250-62. PubMed ID: 12140743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunology of pyelonephritis in the primate model. II. Effect on immunosuppression.
    Roberts JA; Domingue GJ; Martin LN; Kim JC; Rangan SR
    Invest Urol; 1981 Nov; 19(3):148-53. PubMed ID: 6271703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevalence of complement fixation antibodies of cytomegalovirus in various Mexican communities].
    Martín Sosa S; Avilés Sosa EV; Beltrán F
    Bol Med Hosp Infant Mex; 1978; 35(1):13-21. PubMed ID: 202292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
    Aalto SM; Linnavuori K; Peltola H; Vuori E; Weissbrich B; Schubert J; Hedman L; Hedman K
    J Med Virol; 1998 Nov; 56(3):186-91. PubMed ID: 9783683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoprophylaxis of experimental cytomegalovirus infection.
    Minamishima Y
    Ann Microbiol (Paris); 1977 Oct; 128(3):399-407. PubMed ID: 203216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunosuppressive therapy and cytomegalovirus infection in the animal experiment].
    Peller P; Goetz O
    Monatsschr Kinderheilkd (1902); 1975 May; 123(5):404-5. PubMed ID: 176577
    [No Abstract]   [Full Text] [Related]  

  • 32. [Mouse cytomegalovirus infection under cytosine arabinoside treatment].
    Peller P; Goetz O; Rath M
    Infection; 1976; 4(3):130-3. PubMed ID: 185154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice.
    Kelsey DK; Kern ER; Overall JC; Glasgow LA
    Antimicrob Agents Chemother; 1976 Mar; 9(3):458-64. PubMed ID: 176935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immediate loss of cell-mediated immunity to murine cytomegalovirus upon treatment with immunosuppressive agents.
    Mattsson DM; Howard RJ; Balfour HH
    Infect Immun; 1980 Dec; 30(3):700-8. PubMed ID: 6262240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease.
    McCracken GH; Luby JP
    J Pediatr; 1972 Mar; 80(3):488-93. PubMed ID: 4334178
    [No Abstract]   [Full Text] [Related]  

  • 36. Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders.
    Dowling JN; Saslow AR; Armstrong JA; Ho M
    J Infect Dis; 1976 Apr; 133(4):399-408. PubMed ID: 177710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immediate early antigens in human cytomegalovirus infected cells.
    Michelson-Fiske S; Horodniceanu F; Guillon JC
    Nature; 1977 Dec; 270(5638):615-7. PubMed ID: 201863
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of immunosuppression on humoral and cell-mediated immunity to murine cytomegalovirus.
    Howard RJ; Mattson DM; Balfour HH
    Proc Soc Exp Biol Med; 1979 Jul; 161(3):341-6. PubMed ID: 223172
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunosuppression reactivates and disseminates latent murine cytomegalovirus.
    Jordan MC; Shanley JD; Stevens JG
    IARC Sci Publ (1971); 1978; (24 Pt 2):769-74. PubMed ID: 221402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental infection of marmosets with a cytomegalovirus of human origin.
    Nigida SM; Falk LA; Wolfe LG; Deinhardt F; Lakeman A; Alford CA
    J Infect Dis; 1975 Nov; 132(5):582-6. PubMed ID: 171324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.